These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Protein engineering: Regulatory perspectives of stearoyl CoA desaturase.
    Author: Kamal S, Saleem A, Rehman S, Bibi I, Iqbal HMN.
    Journal: Int J Biol Macromol; 2018 Jul 15; 114():692-699. PubMed ID: 29605251.
    Abstract:
    Stearoyl Co A desaturase (SCD) is a rate-limiting lipogenic enzyme that plays an integral role in catalyzing the synthesis of monounsaturated fatty acids, chiefly oleate and palmitoleate. Both contribute a major part of the biological membrane. Numerous SCD isoforms exist in mouse and humans, i.e., SCD-1 to SCD-4 and SCD-1 and SCD-5, respectively. From the biological viewpoint, hyperexpression of SCD1 cause many metabolic disorders including obesity, insulin resistance, hypertension, and hypertriglyceridemia, etc. Herein, an effort has been made to highlight the value of protein engineering in controlling the SCD-1 expression with the involvement of different inhibitors as therapeutic agents. The first part of the review describes Stearoyl CoA desaturase index and different SCD isoforms. Various regulatory aspects of SCD are reviewed in four subsections, i.e., (1) hormonal regulation, (2) regulation by dietary carbohydrates, (3) regulation by green tea, and (4) regulation via polyunsaturated fatty acids (PUFAs). Moreover, the regulation of Stearoyl CoA desaturase expression in the metabolism of fats and carbohydrates is discussed. The third part mainly focuses on natural and synthetic inhibitors. Towards the end, information is also given on potential future considerations of SCD-1 inhibitors as metabolic syndrome therapeutics, yet additional work is required.
    [Abstract] [Full Text] [Related] [New Search]